Amneal Pharmaceuticals et al., 2018-05-07: The 8-K exhibit recording completion of the Amneal-Impax combination on 7 May 2018, the transaction through which Impax's mebendazole product (Emverm) passed to Amneal. It dates the final link in the ownership chain for the US product.
Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. (Impax) today announced that they have completed their business combination to form Amneal Pharmaceuticals, Inc. (Amneal or the Company).
Amneal Pharmaceuticals et al., 2018-05-07: The 8-K exhibit recording completion of the Amneal-Impax combination on 7 May 2018, the transaction through which Impax's mebendazole product (Emverm) passed to Amneal. It dates the final link in the ownership chain for the US product. SEC filing (company document, LINK). Date on the release: May 7, 2018; Impax shares ceased trading on NASDAQ May 4, 2018; Amneal began trading on NYSE as AMRX. The release does not mention mebendazole/Emverm by name – the product link is established by MBA-24 (Impax held Emverm) and MBA-25 (Amneal holds Emverm). Recorded as neutral corporate disclosure.
